← Latest news 
RPG Life Sciences to scale API business and target GLP 1 entry by August September
Business
Published on 30 April 2026
A major acquisition could fast track its GLP 1 bid
RPG Life Sciences says it is doubling down on its API business as the growth engine, while lining up a significant acquisition to expand capacity. The company also plans to enter the GLP-1 weight-loss therapy market by August-September, despite geopolitical risks. Its strategy centers on niche, complex molecules and moving into new therapy areas.
- RPG Life Sciences is prioritizing its API business for future growth
- A major acquisition is planned to scale operations quickly
- GLP-1 entry target is set for August-September timeframe
- Focus remains on complex niche molecules amid geopolitical risks
Read the full story at The Economic Times
This summarization was done by Beige for a story published on 
The Economic Times